Eric Lefkofsky was born and raised in Michigan, which is where he built his academic background. He graduated from the University of Michigan in 1991 with honors. Following this achievement, Eric went back to the University Law School to obtain his degree as a Juris Doctor. This did not pan out exactly as Eric has planned since he instead set his sights on being an entrepreneur which ended up bringing him a tremendous amount of success. It was in 2001 that he started on his journey with InnerWorkings. To follow this up, Eric started up Echo Logistics in 2004. Eric’s true success, however, came in 2007 when he co-founded the massively successful platform, Groupon. Groupon helps customers find deals and coupons on all their favorite things to save them money and is still widely popular today.
Eric not only manages his businesses, like Groupon, but he also manages the Lefkofsky Foundation with his wife, teaches students about tech businesses and entrepreneurship, and serves as a board member for a variety of different organizations, including the Children’s Memorial Hospital and Art Institute in Chicago. Eric has a strong desire to build his success, but a stronger desire still to give back to the community.
There are always new advancements in the fields of technology and healthcare. Despite this and despite all the funding that there is for health care, fighting cancer and providing proper treatment to patients has always been a major challenge. Eric Lefkofksy has taken it upon himself to build a solution for this problem, and that solution is Tempus. Eric co-founded Tempus with Brad Keywell and the company aims to build a massive library of clinical data that can be used by doctors to offer more precise treatments for their patients.
Tempus’ platform is largely made up of analytics software and the goal is to have Tempus compile all the loose data on cancer patients and bring it all together, rather than it all being disorganized. With the new technology for gene sequencing, Tempus believes it can create a database for cancer patients that will allow for precision medicine in these medical practices which will mark a milestone for the industry, especially when it comes to treating cancer.